NeoGenomics provides cancer genetic testing services to oncologists, pathologists, and hospitals. It has experienced strong and consistent growth in revenue and tests performed annually through expanding its test menu, increasing sales force productivity, and gaining market share. The company aims to continue its growth by launching new tests, pursuing partnerships and acquisitions, and capitalizing on the large and growing market for cancer genetic testing fueled by an aging population and advancements in targeted therapies.
Specialized oncology reference laboratory providing the latest testing technologies, global/tech-only options, and interactive education to the pathology community
Offer the complete spectrum of diagnostic services through nationwide network of laboratories
Dedicated to providing superior service, faster turn-around times, and complete attention to the needs of our clients and their patients
NeoGenomics Company Overview 2014-09-12 includes the following sections:
-Forward-looking Statements
-Investment Highlights
-Experienced Management Team
-Company Overview
-Proven Track Record Of Consistent Growth
-U.S. Cancer Testing Market Size $10-12 Billion
-NeoGenomics' Cancer Testing Services
-Customer Targets
-Accelerating Pace of Innovation
-90+ New Assays Launched Since January 2012
-A Growing Commercial & Facility Footprint
-Acquisition of Path Logic
-Strategic Alliance
-2014 and 2015 Strategic Priorities
-Accelerating Cash Flow & Earnings
-Adjusted EBITDA Metrics
- And much more...
March 2017 Company Overview Presentation by NeoGenomics, (Nasdaq: NEO) a fast...Hawk Associates, Inc.
NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory and pharma services company that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, immunohistochemistry, anatomic pathology, and molecular genetics. Headquartered in Fort Myers, FL, NeoGenomics maintains a network of testing facilities across the US. NeoGenomics services the needs of pathologists, oncologists, urologists and other physician specialists, academic institutions, and the pharmaceutical industry.
The company’s acquisition of Clarient at the end of 2015 significantly transformed the company in terms of reach and capabilities. It more than doubled the size of the company overnight and puts the company on a strong path to achieve its vision of becoming the world’s leading cancer testing and information company.
The company has aggressively accelerated its pace of innovation adding new cancer tests. The company’s targeted tumor-specific multimodality NeoTYPE profiles, which combine molecular, FISH and IHC testing, are gaining acceptance by pathologists and clinicians. The new Liquid Biopsy NeoLAB family of tests now includes 16 different liquid biopsy test. Clarient’s expertise in PDL1 testing has further broadened the company’s cancer testing menu.
Specialized oncology reference laboratory providing the latest testing technologies, global/tech-only options, and interactive education to the pathology community
Offer the complete spectrum of diagnostic services through nationwide network of laboratories
Dedicated to providing superior service, faster turn-around times, and complete attention to the needs of our clients and their patients
NeoGenomics Company Overview 2014-09-12 includes the following sections:
-Forward-looking Statements
-Investment Highlights
-Experienced Management Team
-Company Overview
-Proven Track Record Of Consistent Growth
-U.S. Cancer Testing Market Size $10-12 Billion
-NeoGenomics' Cancer Testing Services
-Customer Targets
-Accelerating Pace of Innovation
-90+ New Assays Launched Since January 2012
-A Growing Commercial & Facility Footprint
-Acquisition of Path Logic
-Strategic Alliance
-2014 and 2015 Strategic Priorities
-Accelerating Cash Flow & Earnings
-Adjusted EBITDA Metrics
- And much more...
March 2017 Company Overview Presentation by NeoGenomics, (Nasdaq: NEO) a fast...Hawk Associates, Inc.
NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory and pharma services company that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, immunohistochemistry, anatomic pathology, and molecular genetics. Headquartered in Fort Myers, FL, NeoGenomics maintains a network of testing facilities across the US. NeoGenomics services the needs of pathologists, oncologists, urologists and other physician specialists, academic institutions, and the pharmaceutical industry.
The company’s acquisition of Clarient at the end of 2015 significantly transformed the company in terms of reach and capabilities. It more than doubled the size of the company overnight and puts the company on a strong path to achieve its vision of becoming the world’s leading cancer testing and information company.
The company has aggressively accelerated its pace of innovation adding new cancer tests. The company’s targeted tumor-specific multimodality NeoTYPE profiles, which combine molecular, FISH and IHC testing, are gaining acceptance by pathologists and clinicians. The new Liquid Biopsy NeoLAB family of tests now includes 16 different liquid biopsy test. Clarient’s expertise in PDL1 testing has further broadened the company’s cancer testing menu.
In this NeoGenomics Laboratory Company Overview Presentation 02/19/2014, you will find detail information on the following highlights:
•Fast growing cancer genetics lab servicing Oncologists, Pathologists and Hospitals
•Strategic client partnerships created by “Tech-Only” model
•Dynamic, rapidly-growing and consolidating industry
•Industry-leading revenue & test volume growth
•Strong productivity and operating leverage leading to accelerating cash flow and net income
•Strong Management Team with large cap lab experience
In this NeoGenomics Laboratory Company Overview Presentation 01/09/2014, you will find detail information on the following highlights:
•Fast growing cancer genetics lab servicing Oncologists, Pathologists and Hospitals
•Strategic client partnerships created by “Tech-Only” model
•Dynamic, rapidly-growing and consolidating industry
•Industry-leading revenue & test volume growth
•Strong productivity and operating leverage leading to accelerating cash flow and net income
•Strong Management Team with large cap lab experience
NeoGenomics Forward-looking statements, Investment Highlights, Consistent Historical Growth, Accelerating Cash FLow & Earnings, Management Team, Cancer Testing Services, Customer Targets, NeoGenomics Formula for Success, Industry Dynamics, US Cancer Testing Market Size, Cancer Testing Market Characteristics, Key Growth Drivers Over the Next 3 Years...
NeoGenomics Company Overview highlights. It includes investment highlights, Consistent historical growth charts, accelerating cash flow & earnings, management team, testing services, customer targets, formula for success, industry dynamics, U.S. cancer market size, cancer testing market characteristics, key growth drivers...
This presentation contains statements which constitute forward-looking statements within the meaning of Section 27A of the Securities Act, as amended; Section 21E of the Securities Exchange Act of 1934; and the Private Securities Litigation Reform Act of 1995. The words “may”, “would”, “could”, “will”, “expect”, “estimate”, “anticipate”, “believe”, “intend”, “plan”, “goal”, and similar expressions and variations thereof are intended to specifically identify forward-looking statements. All statements that are not statements of historical fact are forward-looking statements.
Investors and prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors. The risks that might cause such differences are identified in our filings with the Securities and Exchange Commission. We undertake no obligation to publicly update or revise the forward looking statements made in this presentation to reflect events or circumstances after
NeoGenomics is a fast growing cancer genetics lab servicing Oncologists, Pathologists and Hospitals. This is August 2014 Company Overview Presentation.
In this NeoGenomics Laboratory Company Overview Presentation 01/09/2014, you will find detail information on the following highlights:
•Fast growing cancer genetics lab servicing Oncologists, Pathologists and Hospitals
•Strategic client partnerships created by “Tech-Only” model
•Dynamic, rapidly-growing and consolidating industry
•Industry-leading revenue & test volume growth
•Strong productivity and operating leverage leading to accelerating cash flow and net income
•Strong Management Team with large cap lab experience
This presentation contains statements which constitute forward-looking statements within the meaning of Section 27A of the Securities Act, as amended; Section 21E of the Securities Exchange Act of 1934; and the Private Securities Litigation Reform Act of 1995. The words “may”, “would”, “could”, “will”, “expect”, “estimate”, “anticipate”, “believe”, “intend”, “plan”, “goal”, and similar expressions and variations thereof are intended to specifically identify forward-looking statements. All statements that are not statements of historical fact are forward-looking statements.
Investors and prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors. The risks that might cause such differences are identified in our filings with the Securities and Exchange Commission. We undertake no obligation to publicly update or revise the forward looking statements made in this presentation to reflect events or circumstances after the date of this presentation or to reflect the occurrence of unanticipated events.
Social Campus is a software solution that calls all the major entities in the university to collaborate with each other, access and share information presented wisely. The virtue of Social Campus lies in its availability as mobile app on different major handheld devices.
Social Campus makes the university online, socially collaborated, synchronized, organized and more engaged with students.
Company Overview Presentation for NeoGenomics:
•Fast growing cancer genetics lab servicing Oncologists, Pathologists and Hospitals
•Strategic client partnerships created by “Tech-Only” model
•Dynamic, rapidly-growing and consolidating industry
•Industry-leading revenue & test volume growth
•Strong productivity and operating leverage leading to accelerating cash flow and net income
•Strong Management Team with large cap lab experience
NeoGenomics overview presetnation ontains statements which constitute forward-looking statements within the meaning of Section 27A of the Securities Act, as amended; Section 21E of the Securities Exchange Act of 1934; and the Private Securities Litigation Reform Act of 1995. The words “may”, “would”, “could”, “will”, “expect”, “estimate”, “anticipate”, “believe”, “intend”, “plan”, “goal”, and similar expressions and variations thereof are intended to specifically identify forward-looking statements. All statements that are not statements of historical fact are forward-looking statements.
In this NeoGenomics Laboratory Company Overview Presentation 02/19/2014, you will find detail information on the following highlights:
•Fast growing cancer genetics lab servicing Oncologists, Pathologists and Hospitals
•Strategic client partnerships created by “Tech-Only” model
•Dynamic, rapidly-growing and consolidating industry
•Industry-leading revenue & test volume growth
•Strong productivity and operating leverage leading to accelerating cash flow and net income
•Strong Management Team with large cap lab experience
In this NeoGenomics Laboratory Company Overview Presentation 01/09/2014, you will find detail information on the following highlights:
•Fast growing cancer genetics lab servicing Oncologists, Pathologists and Hospitals
•Strategic client partnerships created by “Tech-Only” model
•Dynamic, rapidly-growing and consolidating industry
•Industry-leading revenue & test volume growth
•Strong productivity and operating leverage leading to accelerating cash flow and net income
•Strong Management Team with large cap lab experience
NeoGenomics Forward-looking statements, Investment Highlights, Consistent Historical Growth, Accelerating Cash FLow & Earnings, Management Team, Cancer Testing Services, Customer Targets, NeoGenomics Formula for Success, Industry Dynamics, US Cancer Testing Market Size, Cancer Testing Market Characteristics, Key Growth Drivers Over the Next 3 Years...
NeoGenomics Company Overview highlights. It includes investment highlights, Consistent historical growth charts, accelerating cash flow & earnings, management team, testing services, customer targets, formula for success, industry dynamics, U.S. cancer market size, cancer testing market characteristics, key growth drivers...
This presentation contains statements which constitute forward-looking statements within the meaning of Section 27A of the Securities Act, as amended; Section 21E of the Securities Exchange Act of 1934; and the Private Securities Litigation Reform Act of 1995. The words “may”, “would”, “could”, “will”, “expect”, “estimate”, “anticipate”, “believe”, “intend”, “plan”, “goal”, and similar expressions and variations thereof are intended to specifically identify forward-looking statements. All statements that are not statements of historical fact are forward-looking statements.
Investors and prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors. The risks that might cause such differences are identified in our filings with the Securities and Exchange Commission. We undertake no obligation to publicly update or revise the forward looking statements made in this presentation to reflect events or circumstances after
NeoGenomics is a fast growing cancer genetics lab servicing Oncologists, Pathologists and Hospitals. This is August 2014 Company Overview Presentation.
In this NeoGenomics Laboratory Company Overview Presentation 01/09/2014, you will find detail information on the following highlights:
•Fast growing cancer genetics lab servicing Oncologists, Pathologists and Hospitals
•Strategic client partnerships created by “Tech-Only” model
•Dynamic, rapidly-growing and consolidating industry
•Industry-leading revenue & test volume growth
•Strong productivity and operating leverage leading to accelerating cash flow and net income
•Strong Management Team with large cap lab experience
This presentation contains statements which constitute forward-looking statements within the meaning of Section 27A of the Securities Act, as amended; Section 21E of the Securities Exchange Act of 1934; and the Private Securities Litigation Reform Act of 1995. The words “may”, “would”, “could”, “will”, “expect”, “estimate”, “anticipate”, “believe”, “intend”, “plan”, “goal”, and similar expressions and variations thereof are intended to specifically identify forward-looking statements. All statements that are not statements of historical fact are forward-looking statements.
Investors and prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors. The risks that might cause such differences are identified in our filings with the Securities and Exchange Commission. We undertake no obligation to publicly update or revise the forward looking statements made in this presentation to reflect events or circumstances after the date of this presentation or to reflect the occurrence of unanticipated events.
Social Campus is a software solution that calls all the major entities in the university to collaborate with each other, access and share information presented wisely. The virtue of Social Campus lies in its availability as mobile app on different major handheld devices.
Social Campus makes the university online, socially collaborated, synchronized, organized and more engaged with students.
Company Overview Presentation for NeoGenomics:
•Fast growing cancer genetics lab servicing Oncologists, Pathologists and Hospitals
•Strategic client partnerships created by “Tech-Only” model
•Dynamic, rapidly-growing and consolidating industry
•Industry-leading revenue & test volume growth
•Strong productivity and operating leverage leading to accelerating cash flow and net income
•Strong Management Team with large cap lab experience
NeoGenomics overview presetnation ontains statements which constitute forward-looking statements within the meaning of Section 27A of the Securities Act, as amended; Section 21E of the Securities Exchange Act of 1934; and the Private Securities Litigation Reform Act of 1995. The words “may”, “would”, “could”, “will”, “expect”, “estimate”, “anticipate”, “believe”, “intend”, “plan”, “goal”, and similar expressions and variations thereof are intended to specifically identify forward-looking statements. All statements that are not statements of historical fact are forward-looking statements.
Company Overview Presentation for November 2014.
-Specialized oncology reference laboratory providing the latest testing technologies, global/tech-only options, and interactive education to the pathology community.
-Offer the complete spectrum of diagnostic services in FISH, Flow Cytometry, Cytogenetics, digital pathology, immunohistochemistry, and molecular testing through nationwide network of laboratories
-Dedicated to providing superior service, faster TAT, and complete attention to the needs of our clients and their patients
Cancer Diagnostics Reference Laboratory / NeoGenomics April 2014 investors company overview presentation. This presentation highlights the following:
--Fast growing cancer genetics lab servicing Oncologists, Pathologists and Hostpitals
--Strategic client partnerships created by "Tech-Only" model
--Dynamic, rapidly-growing and consolidating industry
Industry-leading revenue & test volume growth
--Strong productivity and operating leverage leading to accelerating cash flow and net income
--Strong Management Team with large cap lab experience
NeoGenomics Company Overview 07/24/2014. An emerging leader in fastest-growing segment of lab testing industry. They hold a robust competitive advantages and product portfolio. They have a strong management team with outstanding industry experience.
NeoGenomics Company Overview presents investment highlights. It provides details on its growing cancer genetics lab servicing oncologists, pathologists and hospitals, its strategic client partnerships, its dynamic, rapidly-growing and consolidating industry and much more…
Specialized oncology reference laboratory providing the latest testing technologies, global/tech-only options, and interactive education to the pathology community
Offer the complete spectrum of diagnostic services through nationwide network of laboratories
Dedicated to providing superior service, faster turn-around times, and complete attention to the needs of our clients and their patients
Specialized oncology reference laboratory providing the latest testing technologies, global/tech-only options, and interactive education to the pathology community
Offer the complete spectrum of diagnostic services through nationwide network of laboratories
Dedicated to providing superior service, faster turn-around times, and complete attention to the needs of our clients and their patients
Specialized oncology reference laboratory providing the latest testing technologies, global/tech-only options, and interactive education to the pathology community
Offer the complete spectrum of diagnostic services through nationwide network of laboratories
Dedicated to providing superior service, faster turn-around times, and complete attention to the needs of our clients and their patients
Specialized oncology reference laboratory providing the latest testing technologies, global/tech-only options, and interactive education to the pathology community
Offer the complete spectrum of diagnostic services through nationwide network of laboratories
Dedicated to providing superior service, faster turn-around times, and complete attention to the needs of our clients and their patients
Digital Transformation and IT Strategy Toolkit and TemplatesAurelien Domont, MBA
This Digital Transformation and IT Strategy Toolkit was created by ex-McKinsey, Deloitte and BCG Management Consultants, after more than 5,000 hours of work. It is considered the world's best & most comprehensive Digital Transformation and IT Strategy Toolkit. It includes all the Frameworks, Best Practices & Templates required to successfully undertake the Digital Transformation of your organization and define a robust IT Strategy.
Editable Toolkit to help you reuse our content: 700 Powerpoint slides | 35 Excel sheets | 84 minutes of Video training
This PowerPoint presentation is only a small preview of our Toolkits. For more details, visit www.domontconsulting.com
B2B payments are rapidly changing. Find out the 5 key questions you need to be asking yourself to be sure you are mastering B2B payments today. Learn more at www.BlueSnap.com.
VAT Registration Outlined In UAE: Benefits and Requirementsuae taxgpt
Vat Registration is a legal obligation for businesses meeting the threshold requirement, helping companies avoid fines and ramifications. Contact now!
https://viralsocialtrends.com/vat-registration-outlined-in-uae/
Recruiting in the Digital Age: A Social Media MasterclassLuanWise
In this masterclass, presented at the Global HR Summit on 5th June 2024, Luan Wise explored the essential features of social media platforms that support talent acquisition, including LinkedIn, Facebook, Instagram, X (formerly Twitter) and TikTok.
Personal Brand Statement:
As an Army veteran dedicated to lifelong learning, I bring a disciplined, strategic mindset to my pursuits. I am constantly expanding my knowledge to innovate and lead effectively. My journey is driven by a commitment to excellence, and to make a meaningful impact in the world.
Implicitly or explicitly all competing businesses employ a strategy to select a mix
of marketing resources. Formulating such competitive strategies fundamentally
involves recognizing relationships between elements of the marketing mix (e.g.,
price and product quality), as well as assessing competitive and market conditions
(i.e., industry structure in the language of economics).
Buy Verified PayPal Account | Buy Google 5 Star Reviewsusawebmarket
Buy Verified PayPal Account
Looking to buy verified PayPal accounts? Discover 7 expert tips for safely purchasing a verified PayPal account in 2024. Ensure security and reliability for your transactions.
PayPal Services Features-
🟢 Email Access
🟢 Bank Added
🟢 Card Verified
🟢 Full SSN Provided
🟢 Phone Number Access
🟢 Driving License Copy
🟢 Fasted Delivery
Client Satisfaction is Our First priority. Our services is very appropriate to buy. We assume that the first-rate way to purchase our offerings is to order on the website. If you have any worry in our cooperation usually You can order us on Skype or Telegram.
24/7 Hours Reply/Please Contact
usawebmarketEmail: support@usawebmarket.com
Skype: usawebmarket
Telegram: @usawebmarket
WhatsApp: +1(218) 203-5951
USA WEB MARKET is the Best Verified PayPal, Payoneer, Cash App, Skrill, Neteller, Stripe Account and SEO, SMM Service provider.100%Satisfection granted.100% replacement Granted.
Top mailing list providers in the USA.pptxJeremyPeirce1
Discover the top mailing list providers in the USA, offering targeted lists, segmentation, and analytics to optimize your marketing campaigns and drive engagement.
1. 1
NASDAQ: NEO
Company Overview Presentation
July 2013
Time Matters. Results Count!
“Improving Patient Care
through exceptional cancer
genetic testing services!”
2. 22
Forward-looking Statements
This presentation contains statements which constitute forward-looking
statements within the meaning of Section 27A of the Securities Act, as
amended; Section 21E of the Securities Exchange Act of 1934; and the
Private Securities Litigation Reform Act of 1995. The words “may”, “would”,
“could”, “will”, “expect”, “estimate”, “anticipate”, “believe”, “intend”, “plan”,
“goal”, and similar expressions and variations thereof are intended to
specifically identify forward-looking statements. All statements that are not
statements of historical fact are forward-looking statements.
Investors and prospective investors are cautioned that any such
forward-looking statements are not guarantees of future performance and
involve risks and uncertainties, and that actual results may differ materially
from those projected in the forward-looking statements as a result of
various factors. The risks that might cause such differences are identified
in our filings with the Securities and Exchange Commission. We undertake
no obligation to publicly update or revise the forward looking statements
made in this presentation to reflect events or circumstances after the date
of this presentation or to reflect the occurrence of unanticipated events.
3. 33
Investment Highlights
• Fast growing pure-play, cancer genetics lab
• Servicing: Oncologists, Pathologists and Hospitals
• “Tech-Only” model creates strategic client partnerships
• Rapidly growing industry undergoing consolidation
• Strong Management Team with large cap lab experience
• Industry leading revenue & test volume growth driven by
new test innovation and increasing sales force productivity
• Increasing productivity and operating leverage leading to
accelerating cash flow and net income
5. 55
Accelerating Cash Flow & Earnings
($, 000's) 2010 2011 2012
Total Revenue 34,371$ 43,484$ 59,867$
% Growth 16.6% 26.5% 37.7%
Total Gross Margin 15,783 19,428 26,836
Gross Margin % 45.9% 44.7% 44.8%
Sales & Marketing Exp as a % of Rev 21.8% 16.0% 12.5%
Gen & Admin Exp as a % of Rev 31.2% 28.4% 26.5%
R&D Exp as a % of Rev 1.5% 1.2% 3.8%
SG&A Expenses 18,746 19,837 25,624
Total SG&A as a % of Rev 54.5% 45.6% 42.8%
Adjusted EBITDA (566)$ 2,134$ 5,997$
% Growth NA 181.0%
Net Income/(Loss) (3,303)$ (1,177)$ 65$
Diluted EPS ($0.09) ($0.03) $0.00
Summary Operating Metrics
Avg. Revenue/Test 600$ 570$ 522$
% Change -7.1% -4.9% -8.4%
6. 66
Management Team
• Douglas VanOort, Chairman & CEO
Operating Partner, Summer Street Capital Partners;
Chief Operating Officer, Quest Diagnostics
• Maher Albitar, M.D., Chief Medical Officer & Director of R&D
Med. Dir. for Hematopathology & Oncology and Chief of R&D, Quest Nichols Institute;
Director of Leukemia and Molecular Laboratory, MD Anderson Cancer Center
• Robert Gasparini, Director & Chief Scientific Officer
Director of Genetics, U.S. Labs; Worldwide Marketing Mgr., Ventana Medical Systems;
Asst. Director, Prenatal Diagnostic Center (Harvard)
• Steven Jones, Director, EVP – Finance, & Chief Compliance Officer
Chairman, Aspen Capital Group; Managing Member, Medical Venture Partners;
Vice President, Merrill Lynch Investment Banking
• George Cardoza, Chief Financial Officer
CFO, Protocol Global Solutions; Controller, Central Region, Quest Diagnostics
• Robert Horel, Vice President, Sales & Marketing
Regional Mgr., US Labs; Product Specialist, Ventana Medical Systems; Pilot, U.S. Navy
• Steven Ross, Chief Information Officer
Vice President Technology, Chico’s FAS, Inc.
7. 77
NeoGenomics’ Cancer Testing Services
Key Testing Modalities
Cytogenetics: chromosome analysis
- “Neighborhood view of 46 houses from 1000 feet”
Flow Cytometry & IHC: cell surface marker
analysis
- “Single house view from 500 feet”
Fluorescence in-situ Hybridization (FISH):
gene analysis - “Door and window view of one house”
Molecular testing: DNA/RNA analysis
-“View of serial number on door lock”
8. 88
Business Model Targets
Pathologists and Hospital Pathology Groups (71% of Q1 Revenue)
• Innovative technical component (TC) only services – Flow, FISH, IHC
• Enables community pathologists to compete with large labs
• Rapid turnaround-time and web-based reporting
• Extensive training programs
Oncologists and Clinician Groups (23% of Q1 Revenue)
• Includes Oncologists, Dermatologist, Urologists
• Specialized high level of service and outstanding quality for clinicians
• Genetic Pathology Solutions™ (GPS) reporting – all relevant case data on one page
report
• Increasing Opportunity to service larger practices with Tech-only model
Other (6% of Revenue)
• Contract research/clinical trial support work for Pharma clients
• Reference laboratories
9. 99
Industry Dynamics
& Demographics
• Aging U.S. population and
prevalence of cancer
• Diagnostic testing reduces
healthcare costs and improves
clinical outcomes
• Emergence of molecular diagnostics
• Targeted therapeutics and
companion diagnostics
• Capitalize on new healthcare
paradigm
• Attract New Customers
– Promote key advantages of
“tech-only” model
– Partner with Clinician Offices
• Grow existing customer base
– Sales force productivity
– Increase share of wallet
– Promote product education
– Capitalize on competitor turmoil
• Sustainable revenue growth opportunity
• Significant degree of operating leverage in
the business model
New Products &
Solutions
Market Share Gains
• Continue to expand test menu
• Sublicensing of HDC products
– Cytogenetics/Flow/IHC systems
– Prostate/colon/pancreatic Cx Tests
– International opportunities
• Proprietary test development
• Disruptive technology for select solid
tumor cancers
• Seek new R&D partnerships
Superior Financial Model
NeoGenomics Formula for Success
CONFIDENTIAL
10. 1010
• Molecular diagnostics transforming lab services
industry and fueling rapid growth
– Molecular diagnostics enable physicians to better
diagnose diseases and predict therapeutic efficacy
• Clinical Benefits: Effective treatment at an early stage
increases patient survival rates
• Healthcare Savings: a) forego spending on ineffective
therapies and b) effective intervention at an early stage
generally lowers overall treatment cost
– Need for companion diagnostics being driven by rising
drug costs and an increase in targeted therapeutics
• Xalkori® - Cost of ~$90,000 annually to treat non-small cell
lung cancer. 50 – 61% effective for the ~3% of the
population with certain genetic characteristics
• Diagnostic testing can significantly lower
healthcare costs and improve clinical outcomes
– Diagnostics represents only 2-3% of total healthcare
spend but influence approximately 70% - 80% of
physician decisions
• Cancer prevalence expected to increase as U.S.
population ages
– 77% of all cancers diagnosed are in people age 55 or
older, the fastest growing segment of the US
16%
17% 16%
18%
22%
25% 25% 26%
11%
13% 12% 13%
16%
19% 20% 20%
0%
5%
10%
15%
20%
25%
30%
1980 1990 2000 2010 2020 2030 2040 2050
PercentOfPopulation
Age 60 and older Age 65 and older
Current
U.S. Population Demographics
Boomer Impact on Cancer Market
Industry Dynamics
11. 1111
U.S. Cancer Testing Market: $10-12 Billion
Hematopoietic
Cancers
Solid Tumor Cancers
Total Testing Market: $3 - 4 Billion $7 - 8 Billion
Est. Genetic Mkt. (TAM) ~$1 - 2 Billion ~$1 - 2 Billion
Patients in Treatment: 850,000 7.0 million
New Diagnoses/Yr.: 150,000 1.45 million
Specimen Types: Bone Marrow (350K/Yr)
Per. Blood (150K/Yr)
Lymph Nodes
Tiss. Biopsies (8-10MM)
Fine Needle Aspirates
Other Bodily Fluids
TAM % Neo Addresses: 90-100% 50-60%
Neo Revenue Split: ~80% ~20%
12. 1212
Cancer Testing Market Characteristics
• Highest growth segment of lab Industry
- ~20% annual growth in genetics testing
- ~8% annual growth in related AP testing
• Approx. 360 Genetic Labs in the U.S.
- 2/3 affiliated with academic institutions
- Approximately 20% perform 80% of testing
- Only 15-20 labs with national reach
• High pace of consolidation - Recent examples include:
Target Acquiror TV/LTM Rev
Caris Diagnostics Miraca 3.5x
Genoptix Novartis 1.7x
Clarient GE Healthcare Svcs 5.8x
Genzyme Genetics LabCorp 2.5x
14. 1414
2011
4 molecular
tests
3 FISH
FL – IHC menu
2012
10-color Flow Cytometry
Implemented State-of-the-art
MolDx platform in lieu of Kits
30 new Molecular Assays
Proprietary method for increasing
sensitivity of Sanger sequencing
7 NeoTYPE MolDx Panels
New Aperio Digital Image Analysis
SVM for ALK FISH (Patent App)
Barrett’s Esoph. FISH (Patent App)
NeoARRAY/SNP Cytogenetics
Internalized 99% of send-outs
2013 (In Progress)
25-35 new Molecular tests
Add’l NeoTYPE Panels
Next Generation
Sequencing (48 genes)
ROS1 FISH
NeoSITE Melanoma FISH
Plasma/Urine-based
Prostate Test (Patent App)
SVM-based Cytogenetics
Analysis System
SVM-based Automated
FISH Analysis System v2
Accelerating Pace of Innovation
16. 1616
• Additional Sales Representatives
• Lab Collaboration Initiatives (LCI’s) with large Oncology groups
- Recent addition of 4 Oncology Business Development Mgrs
• New Aperio Image Analysis Platform (just starting full scale roll-out)
• Further penetration of Solid Tumor Market (IHC, etc.)
• Continued outsize growth in molecular assays and panels
• Accelerating growth in 10 color flow cytometry
• Significant traction in clinical trials support work
• Next generation sequencing
• NeoSCORE Prostate Cancer Test
• Other proprietary tests
• M&A Opportunities
Key Growth Drivers Over the Next 3 Years
CONFIDENTIAL
17. 1717
Productivity Increases Have Offset Changes in
Average Revenue/Test to Keep Margins Stable
(1) Productivity calculated as the average number of lab tests completed per month per laboratory FTE.
(2) The Medicare Technical Component Grandfather expiration took effect on 7/1/12, which resulted in a 7.3% sequential decrease in Avg. Unit Price.
(2)
47.3% 48.4%
46.1%
44.7% 44.6% 43.9% 44.5% 44.8% 45.2%
47.1% 47.2%
41.5%
43.2% 46.3%
-20.5%
43.4%
-50%
-40%
-30%
-20%
-10%
0%
10%
20%
30%
40%
50%
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Q409
Q110
Q210
Q310
Q410
Q111
Q211
Q311
Q411
Q112
Q212
Q312
Q412
Q113
Gross Margin % Cum Change in Avg Rev/Test Cum Change in Productivity(1)
18. 1818
Operating Cost per Test & Adj. EBITDA Margin
$723
$642 $642
$671
$649
$618
$576 $565
$555 $531
$512
$526 $482 $478
-12%
-1%
-2%
-5%
0%
-1%
5%
6%
8%
12% 12%
6% 10%
11%
-15%
-10%
-5%
0%
5%
10%
15%
$0
$100
$200
$300
$400
$500
$600
$700
$800
Q409 Q110 Q210 Q310 Q410 Q111 Q211 Q311 Q411 Q112 Q212 Q312 Q412 Q113
Cogs Cost/Test G&A Net of R&D Cost/Test S&M Cost/Test
R&D Cost/Test Total Cost/Test Adj EBITDA Margin %
Cost Management & Operating Leverage Have
Resulted In a 33% Reduction in Total Costs Per Test
19. 1919
Quarterly Financial Information
($, 000's) Q4 11 Q1 12 Q2 12 Q3 12 * Q4 12 * Q1 13 *
Total Revenue 12,893$ 15,160$ 15,611$ 14,202$ 14,893$ 15,657$
% Growth (YoY) 47.3% 72.2% 49.2% 25.5% 15.5% 3.3%
% Growth (QoQ) 13.9% 17.6% 3.0% -9.0% 4.9% 5.1%
Total Gross Margin 5,834 7,144 7,367 5,892 6,434 7,246
Gross Margin % 45.2% 47.1% 47.2% 41.5% 43.2% 46.3%
Sales & Marketing Exp 1,801 2,036 1,934 1,839 1,692 1,931
General & Administrative Exp 3,530 3,750 4,066 3,930 4,097 4,175
Research & Development Exp 127 497 528 808 448 835
Total SG&A (Incl R&D) Expenses 5,459 6,283 6,528 6,576 6,237 6,942
SG&A as a % of Rev 42.3% 41.4% 41.8% 46.3% 41.9% 44.3%
Net Income/(Loss) 152$ 603$ 551$ (975)$ (113)$ 3$
Diluted EPS $0.00 $0.01 $0.01 ($0.02) ($0.00) ($0.00)
Adjusted EBITDA 1,055$ 1,775$ 1,943$ 842$ 1,439$ 1,794$
Summary Operating Data
% Growth in Tests Performed (YoY) 57.2% 74.9% 57.1% 41.7% 35.3% 19.1%
Avg. Revenue/Test 572$ 563$ 541$ 502$ 488$ 488$
* Quarterly financials impacted by a reduction in revenue of $1.3 MM/Qtr as a result of the expiration of the Medicare TC Grandfather Clause.
20. 2020
Key Financial Information
Recent Share Price (7/1/13): $ 3.98
Common Shares Outstanding: 48.7 M
Current Market Cap: $193.8 M
Diluted Shares (MRQ, Pro Forma): 50.9 M
Fully Diluted Shares: 55.8 M
Non-affiliate Float Shares: 41.1 M
52 Week Low/High: $1.55/$4.20
Avg. Daily Trading Volume (3 Mos): 194,395
21. 2121
NeoGenomics Summary
• Emerging leader in the fastest growing segment of the
lab testing industry
• Robust competitive advantages and product portfolio
• Strong Management Team with directly relevant industry
experience
• Accelerating profitability propelled by revenue growth
and increased operating leverage
• Q2 2013 guidance: $15.8 - $16.4 million of revenue
with $0.00 – $0.01 per share of net income
• Fiscal 2013 guidance: $68 - $73 million of revenue with
$0.03 - $0.05 per share of net income